Cancer Facts & Epidemiological Statistics
Comprehensive clinical data, global incidence benchmarks, survival rate statistics, and modern epidemiological trends.
General Facts & Overview
Cancer remains one of the leading causes of morbidity and mortality worldwide. However, advances in precision genomics, biomarker-driven clinical trials, and early population screening have yielded significant improvements in overall 5-year survival rates over the past three decades.
- Over 100 distinct histological cancer types have been classified, with solid epithelial carcinomas comprising the large majority.
- Approximately 1 in 2 men and 1 in 3 women will be diagnosed with an invasive cancer during their lifetime.
- The overall 5-year relative cancer survival rate has risen from 49% in the 1970s to over 68% today across all combined cancer sites.
Global & United States Incidence & Mortality Data
- Global Incidence: Over 20 million new cancer cases are diagnosed annually worldwide, resulting in approximately 9.7 to 10 million deaths.
- U.S. Annual Burden: Approximately 2.0 million new cancer diagnoses and ~610,000 cancer-related deaths per year.
- Leading Causes of Cancer Mortality: Lung and bronchus cancer accounts for the highest mortality burden, followed by colorectal, pancreatic, breast, and prostate cancers.
Top Most Common Cancers & 5-Year Survival Benchmarks
| Cancer Type |
Estimated Annual New Cases |
5-Year Relative Survival Rate |
Key Prognostic Determinants |
| Breast Cancer (Female) |
~310,000 |
~91% (Overall) / >99% (Localized) |
ER/PR/HER2 receptor status, Oncotype DX score, lymph node staging |
| Prostate Cancer |
~299,000 |
~97% (Overall) / >99% (Local/Regional) |
PSA velocity, Gleason score, genomic decipher risk score |
| Lung & Bronchus Cancer |
~234,000 |
~25% (Overall) / ~63% (Localized) |
Histology (NSCLC vs SCLC), EGFR/ALK/KRAS driver mutations, PD-L1 |
| Colorectal Cancer |
~152,000 |
~65% (Overall) / ~91% (Localized) |
MSI/MMR status, KRAS/NRAS/BRAF mutations, stage at colonoscopy |
| Melanoma (Skin) |
~100,000 |
~94% (Overall) / >99% (Localized) |
Breslow tumor thickness, ulceration status, BRAF V600E mutation |
Key Epidemiological Trends
Progress in modern oncology is driven by 3 primary pillars: population-wide tobacco reduction, widespread screening compliance (mammograms, colonoscopies, Pap/HPV tests), and biomarker-matched targeted/immunotherapies.
- Declining cigarette smoking rates have driven a steady drop in lung cancer incidence and mortality over the last 25 years.
- Widespread adoption of HPV vaccination is drastically cutting cervical cancer rates among vaccinated cohorts.
- Increased emphasis is now placed on curbing rising rates of early-onset colorectal cancer through lowered screening age recommendations (starting at age 45).
